Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – What’s Next?

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped down prior to trading on Thursday. The stock had previously closed at $9.06, but opened at $8.66. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.97, with a volume of 419 shares trading hands.

Analyst Upgrades and Downgrades

SGIOY has been the topic of several analyst reports. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a 50 day moving average of $9.10 and a 200 day moving average of $9.42. The stock has a market capitalization of $15.21 billion, a price-to-earnings ratio of 8.94, a price-to-earnings-growth ratio of 3.26 and a beta of 0.08. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. As a group, equities research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.